← Back to Screener
Biodexa Pharmaceuticals plc American Depositary Shs (BDRX)
Price$3.36
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-93.09%
Price vs S&P 500 (4W)-20.93%
VGM Score20.90
Market Capitalization$2.07M
All Metrics
Book Value / Share (Quarterly)$0.00
P/TBV (Annual)0.19x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.00
Price vs S&P 500 (YTD)-78.55%
Net Profit Margin (TTM)-1858.01%
EPS (TTM)$-0.01
10-Day Avg Trading Volume0.03M
EPS Excl Extra (TTM)$-0.01
EPS (Annual)$-0.00
ROI (Annual)-55.68%
Net Profit Margin (5Y Avg)-2372.66%
Cash / Share (Quarterly)$0.00
ROA (Last FY)-35.12%
EBITD / Share (TTM)$-0.00
ROE (5Y Avg)-114.10%
Operating Margin (TTM)-2103.41%
Cash Flow / Share (Annual)$-0.00
P/B Ratio0.10x
P/B Ratio (Quarterly)0.09x
Net Income / Employee (Annual)$-776,886
Net Interest Coverage (TTM)-53.58x
ROA (TTM)-38.69%
EPS Incl Extra (Annual)$-0.00
Current Ratio (Annual)2.03x
Quick Ratio (Quarterly)1.43x
3-Month Avg Trading Volume0.54M
52-Week Price Return-94.16%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.00
P/S Ratio (Annual)3.05x
Asset Turnover (Annual)0.04x
52-Week High$66.50
Operating Margin (5Y Avg)-2597.68%
EPS Excl Extra (Annual)$-0.00
CapEx CAGR (5Y)27.02%
26-Week Price Return-85.17%
Quick Ratio (Annual)1.43x
13-Week Price Return-29.11%
Total Debt / Equity (Annual)0.01x
Current Ratio (Quarterly)2.03x
Enterprise Value$-9.79M
Asset Turnover (TTM)0.04x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-1964.57%
Cash / Share (Annual)$0.00
3-Month Return Std Dev154.76%
Net Income / Employee (TTM)$-776,886
ROE (Last FY)-55.98%
EPS Basic Excl Extra (Annual)$-0.00
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.01x
EPS Incl Extra (TTM)$-0.01
Receivables Turnover (Annual)0.00x
ROI (TTM)-54.56%
P/S Ratio (TTM)3.05x
Pretax Margin (5Y Avg)-2539.69%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.00
Price vs S&P 500 (52W)-118.52%
Year-to-Date Return-70.40%
5-Day Price Return1.20%
EPS Normalized (Annual)$-0.00
ROA (5Y Avg)-64.38%
Net Profit Margin (Annual)-1858.01%
Month-to-Date Return-3.17%
EBITD / Share (Annual)$-0.00
Operating Margin (Annual)-2103.41%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-101.51%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.01
P/TBV (Quarterly)0.19x
P/B Ratio (Annual)0.09x
Pretax Margin (TTM)-1964.57%
Book Value / Share (Annual)$0.00
Price vs S&P 500 (13W)-37.37%
Beta1.19x
Revenue / Share (TTM)$0.00
ROE (TTM)-55.90%
52-Week Low$2.86
mGradeD
vgmGradeD
Show chart for
Analyst Recommendations
Dec 2025
Jan 2026
Feb 2026
Mar 2026
4.29
4.29
4.29
4.29
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
BDRXBiodexa Pharmaceuticals plc American Depositary Shs | — | — | D | $3.36 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Biodexa Pharmaceuticals develops therapies targeting diseases with significant unmet medical needs. The clinical-stage company's pipeline spans familial adenomatous polyposis, non-muscle invasive bladder cancer, type 1 diabetes, and orphan brain cancers.